



February 25, 2015

Fate Therapeutics to Present at Cowen & Company 35th Annual Health Care Conference

SAN DIEGO, Feb. 25, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced that Christian Weyer, M.D., M.A.S., President and Chief Executive Officer, will present at the Cowen & Company 35th Annual Health Care Conference on Wednesday, March 4, 2015 at 11:20 am EST in Boston, MA.

A live webcast of the presentation will be available through the investor relations section of the Company's website at www.fatetherapeutics.com. Following the live webcast, an archived replay will be available on the Company's website for 30 days after the conference.

About Fate Therapeutics, Inc.

Fate Therapeutics is a clinical-stage biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases. The Company's approach utilizes established pharmacologic modalities, such as small molecules, to program the function and fate of cells *ex vivo*. The Company's lead product candidate, PROHEMA®, is an *ex vivo* programmed hematopoietic cellular therapeutic, which is currently in clinical development for the treatment of hematologic malignancies and rare genetic disorders in patients undergoing hematopoietic stem cell transplantation. The Company is also developing *ex vivo* programmed hematopoietic and myogenic cellular therapeutics using its patent-protected induced pluripotent stem cell technology. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.

CONTACT: Renee Leck, Stern Investor Relations, Inc.

212.362.1200, renee@sternir.com